Acoramidis Linked to Lower Mortality Through 54 Months - Summary - MDSpire
From the Journals
Conference News

Acoramidis Linked to Lower Mortality Through 54 Months

Early treatment was associated with sustained reductions in mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy

Share

Early and continuous therapy with acoramidis significantly reduced mortality and cardiovascular hospitalizations over 54 months in patients with transthyretin amyloid cardiomyopathy, as reported by a study led by Dr. Prem Soman from the University of Pittsburgh Medical Center. In a multicenter trial, 389 patients were followed, showing a 45% lower risk of all-cause mortality and a 49% lower risk of cardiovascular mortality for those continuously treated. Functional and biomarker improvements were noted, emphasizing the importance of timely treatment initiation.

Original Source(s)

Acoramidis Linked to Lower Mortality Through 54 Months

  • by Andrea Surnit

  • April 3, 2026

Related Content

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

Extended anticoagulation lowered symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism.

AGA May Signal Lipids, Female Obesity

Sex-stratified cohort links alopecia to hyperlipidemia in both sexes and obesity in females

Mediterranean Diet Linked to Higher Levels of Mitochondrial Microproteins

Greater adherence was associated with lower oxidative stress markers in older patients.